Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 11/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3578944 | 0.83 | RXFP1 (0.62) | RXFP1KDM4ENPSR1ALDH1A1L3MBTL1 | |
| SCHEMBL14094953 | 0.82 | RXFP1 (0.66) | RXFP1KDM4ENPSR1ALDH1A1L3MBTL1 | |
| SCHEMBL12363914 | 0.81 | ALDH1A1 (0.62) | RXFP1KDM4ENPSR1ALDH1A1L3MBTL1 | |
| SCHEMBL3579867 | 0.81 | RXFP1 (0.60) | RXFP1KDM4ENPSR1ALDH1A1L3MBTL1 | |
| SCHEMBL15184304 | 0.80 | CYP1A2 (0.48) | RXFP1KDM4ENPSR1ALDH1A1L3MBTL1 | |
| SCHEMBL189044 | 0.79 | RXFP1 (1.00) | RXFP1KDM4ENPSR1ALDH1A1L3MBTL1 | |
| SCHEMBL2302821 | 0.79 | RXFP1 (0.57) | RXFP1KDM4ENPSR1ALDH1A1L3MBTL1 | |
| SCHEMBL3570447 | 0.79 | RXFP1 (0.54) | RXFP1KDM4ENPSR1ALDH1A1L3MBTL1 | |
| SCHEMBL10044529 | 0.78 | RXFP1 (0.62) | RXFP1KDM4ENPSR1ALDH1A1L3MBTL1 | |
| SCHEMBL2302031 | 0.78 | ALDH1A1 (0.78) | RXFP1KDM4ENPSR1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | claimed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | claimed |
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8614215-B2 | Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) | MERCK SERONO SA (CH) | 2013-12-24 | — | — | US | disclosed |
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | MERCK SERONO S.A. GENEVA (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | MERCK SERONO S.A. GENEVA (CH) | 2013-08-15 | — | — | US | disclosed |
| WO-2012052420-A1 | METHOD FOR PREPARING SUBSTITUTED N-(3-AMINO-QUINOXALIN-2-YL)-SULFONAMIDES AND THEIR INTERMEDIATES N-(3-CHLORO-QUINOXALIN-2-YL)SULFONAMIDES | MERCK SERONO S.A. GENEVA (CH) | 2012-04-26 | — | — | WO | disclosed |
| EP-2118076-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | Merck Serono S.A. (CH) | 2009-11-18 | — | — | EP | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
| EP-1917252-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | PFKP, PDXK, PF4 | RXFP1 1332/4885KDM4E 2803/4885NPSR1 2581/4885 |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | PI4KA, PIP5K1B, PDPK1 | RXFP1 4100/4885KDM4E 2673/4885NPSR1 3391/4885 |
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | STS, NQO2, ASNS | RXFP1 3539/4885KDM4E 2423/4885NPSR1 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.